AU2020295989A1 - Methods and compositions for treating inflammatory conditions - Google Patents

Methods and compositions for treating inflammatory conditions Download PDF

Info

Publication number
AU2020295989A1
AU2020295989A1 AU2020295989A AU2020295989A AU2020295989A1 AU 2020295989 A1 AU2020295989 A1 AU 2020295989A1 AU 2020295989 A AU2020295989 A AU 2020295989A AU 2020295989 A AU2020295989 A AU 2020295989A AU 2020295989 A1 AU2020295989 A1 AU 2020295989A1
Authority
AU
Australia
Prior art keywords
seq
peptide
par3
derived
pari
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020295989A
Other languages
English (en)
Inventor
John H. Griffin
Laura D. HEALY
Laurent O. Mosnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2020295989A1 publication Critical patent/AU2020295989A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
AU2020295989A 2019-06-18 2020-06-17 Methods and compositions for treating inflammatory conditions Pending AU2020295989A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862977P 2019-06-18 2019-06-18
US62/862,977 2019-06-18
PCT/US2020/038036 WO2020257221A1 (en) 2019-06-18 2020-06-17 Methods and compositions for treating inflammatory conditions

Publications (1)

Publication Number Publication Date
AU2020295989A1 true AU2020295989A1 (en) 2022-01-20

Family

ID=74040112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020295989A Pending AU2020295989A1 (en) 2019-06-18 2020-06-17 Methods and compositions for treating inflammatory conditions

Country Status (6)

Country Link
US (1) US20220313780A1 (https=)
EP (2) EP4461303A3 (https=)
JP (2) JP7818405B2 (https=)
CN (1) CN114258317B (https=)
AU (1) AU2020295989A1 (https=)
WO (1) WO2020257221A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120518705A (zh) * 2025-07-23 2025-08-22 中国海洋大学 一种多肽类化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965343A (en) 1988-01-28 1990-10-23 Hoffmann-La Roche Inc. Method of peptide synthesis
US5849954A (en) 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
US5892014A (en) * 1996-10-30 1999-04-06 The Regents Of The University Of California DNA encoding a protease-activated receptor 3
CN1308671A (zh) * 1998-05-05 2001-08-15 科里克萨公司 髓磷脂碱性蛋白肽及其应用
ATE281472T1 (de) 1999-08-02 2004-11-15 Synt Em Sa Berechnungsmethoden zur herstellung von molekularen mimetika
US7271256B2 (en) 2000-02-04 2007-09-18 New England Biolabs, Inc. Method for producing circular or multimeric protein species in vivo or in vitro and related methods
JP4798921B2 (ja) * 2000-03-06 2011-10-19 バイオシーク インコーポレーティッド 機能相同性スクリーニング
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
FR2841559A1 (fr) * 2002-06-28 2004-01-02 Pfizer Recepteurs par modifies, preparation et utilisations
GB0224013D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy
WO2004056309A2 (en) * 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
AU2006242449A1 (en) 2005-04-29 2006-11-09 (Osi) Eyetech, Inc. VEGF variants
US20080090760A2 (en) 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
CN101801462A (zh) * 2007-07-13 2010-08-11 健泰科生物技术公司 用于癌症、炎性病症和自身免疫性病症的治疗和诊断
WO2013070256A2 (en) * 2011-11-07 2013-05-16 The Scripps Research Institute Protease activated receptor-1 (par1) derived cytoprotective polypeptides and related methods
CN104470943B (zh) * 2012-07-03 2017-07-14 一洋药品株式会社 新肽及其用途
WO2017173346A1 (en) * 2016-04-01 2017-10-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Par3 mimetic peptides and uses thereof
CA3075833C (en) * 2017-09-18 2024-06-11 BH Biotech Pty Ltd Composition comprising withania extract, omega-3 fatty acids and natural product extracts and uses thereof

Also Published As

Publication number Publication date
US20220313780A1 (en) 2022-10-06
EP4461303A2 (en) 2024-11-13
JP7818405B2 (ja) 2026-02-20
EP3986560A4 (en) 2023-10-18
JP2022536797A (ja) 2022-08-18
JP2025172264A (ja) 2025-11-21
CN114258317B (zh) 2025-03-14
EP4461303A3 (en) 2025-05-14
EP3986560A1 (en) 2022-04-27
WO2020257221A1 (en) 2020-12-24
CN114258317A (zh) 2022-03-29

Similar Documents

Publication Publication Date Title
AU2005279308B2 (en) Protease resistant human and non-human HMGB1 Box-A mutants and their therapeutic/diagnostic use
AU2017261525A1 (en) Water soluble membrane proteins and methods for the preparation and use thereof
AU2017336440A1 (en) Therapeutic MOTS-c related peptides
US9254309B2 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US8883718B2 (en) Treating cancer
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
JP2016505639A (ja) Ｋｖ１．３アンタゴニスト及び使用方法
Vilar et al. Heterodimerization of p45–p75 modulates p75 signaling: structural basis and mechanism of action
CA2931694A1 (en) Fatty acid derivatives of dimeric peptide ligands of psd-95 and use thereof for treating excitotoxic disease
JP2025172264A (ja) 炎症性状態を処置するための方法および組成物
CN112351993A (zh) 修饰的免疫调节肽
WO2004099238A1 (en) NOVEL mu-CONOTOXIN PEPTIDES
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
WO2024145365A2 (en) Compositions for the diagnosis, treatment, prevention, and alleviation of neurodegenerative and autoimmune disorders
KR20250163313A (ko) Tnf-알파 결합제 및 이를 사용하는 방법
HK1229227B (en) Fatty acid derivatives of dimeric inhibitors of psd-95